ReviewDrug design, development and therapy2020
Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives.
Review in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 358 citations in OpenAlex.
- Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma.Drug delivery · 2026Article
- Lighting up cancer: latest discoveries in ruthenium(ii) polypyridyl complexes for anticancer photodynamic therapy.RSC advances · 2026Review
- River Water Quality Modulates Lupeol Targeting of HIF-1α/VEGF and PI3K/Akt Signaling Pathways in Triple-Negative Breast Cancer Cells.Cell biochemistry and biophysics · 2026Article
- Piano-Stool Ru (II) Complexes as Modulators of Human Prion Protein PrPChemMedChem · 2026Article
- Review
- Reversible Coordination Modes in Piperazine-Based Ru(II)-p-Cymene Acylthiourea Complexes: Modulating DNA Groove Binding for Selective Antimelanoma Activity.ChemMedChem · 2026Article
- NMR of nuclei bound to a paramagnetic metal centre: the case ofChemical science · 2026Article
- Inhibition and disruption of bacterial biofilms by a bipyridine-ruthenium complex: a broad-spectrum in vitro study.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Gold- and Platinum-Peptide Bioconjugates in Cancer Therapy: Recent Advances and Future Directions.Pharmaceutics · 2026Review
- Article
- Coordination chemistry-enabled drug delivery systems: metal-ligand platforms for controlled release and targeted therapeutics.Journal of nanobiotechnology · 2026Review
- Heterometallic Multinuclear Ruthenium Complexes as Cytotoxic Agents.Biomedicines · 2026Review
- Article
- Article
- Multifaceted Applications of Ruthenocene and Its Derivatives in Biomedicine, Energy Storage and Electrochemical Sensing.Biosensors · 2026Review
- In Vitro and In Vivo Effects of a Copper(II)-Hydrazone Complex Against Human Osteosarcoma.Pharmaceutics · 2026Article
- Ru-Based NSAIDs as Potential Anticancer Therapeutics.Molecules (Basel, Switzerland) · 2026Article
- A novel Ru(II) complex with pyrene-1-carbaldehyde hydrazone: structural, electronic, theoretical, and biological studies.Frontiers in chemistry · 2026Article
- Metal carcinogens and cancer: integrating genetic and epigenetic perspectives.Frontiers in oncology · 2026Review
- ADMET Profiling of the Metallodrugs: A Comparative Review of Platinum, Palladium, Gold, Ruthenium, Copper, and Zinc Anticancer Complexes.Bioinorganic chemistry and applications · 2026Review
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum (Pt)-based anticancer drugs such as cisplatin have been used to treat various cancers. However, they have some limitations including poor selectivity and toxicity towards normal cells and increasing chemoresistance. Therefore, there is a need for novel metallo-anticancers, which has not been met for decades. Since the initial introduction of ruthenium (Ru) polypyridyl complex, a number of attempts at structural evolution have been conducted to improve efficacy. Among them, half-sandwich Ru-arene complexes have been the most prominent as an anticancer platform. Such complexes have clearly shown superior anticancer profiles such as increased selectivity toward cancer cells and ameliorating toxicity against normal cells compared to existing Pt-based anticancers. Currently, several Ru complexes are under human clinical trials. For improvement in selectivity and toxicity associated with chemotherapy, Ru complexes as photodynamic therapy (PDT), and photoactivated chemotherapy (PACT), which can selectively activate prodrug moieties in a specific region, have also been investigated. With all these studies on these interesting entities, new metallo-anticancer drugs to at least partially replace existing Pt-based anticancers are anticipated. This review covers a brief description of Ru-based anticancer complexes and perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.